FDA Grants Antifungal Orphan Drug Status for Valley Fever
Viamet announced that the Food and Drug Administration (FDA) has granted Orphan Drug designation to VT-1598 for the treatment of coccidioidomycosis or Valley Fever, a common lung infection in the southwestern US.
VT-1598 has demonstrated significantly greater potency than fluconazole against Coccidioides isolates in preclinical studies. In addition, oral VT-1598 has also demonstrated high efficacy in treating Coccidioides disease disseminated to the central nervous system. It also exhibits potent activity against other endemic fungi, including Histoplasma and Blastomyces
VT-1598 is a selective, oral inhibitor of fungal CYP51.
For more information visit Viamet.com.